BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. Front Immunol 2022;13:801522. [PMID: 35222380 DOI: 10.3389/fimmu.2022.801522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Chatterjee S, Bhattacharya M, Dhama K, Lee SS, Chakraborty C. Can the RBD mutation R346X provide an additional fitness to the "variant soup," including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance? Mol Ther Nucleic Acids 2023;32:61-3. [PMID: 36938362 DOI: 10.1016/j.omtn.2023.02.030] [Reference Citation Analysis]
2 Torres P, Sancho-Saldaña A, Gil Sánchez A, Peralta S, Solana MJ, Bakkioui S, González-Mingot C, Quibus L, Ruiz-Fernández E, San Pedro-Murillo E, Brieva L. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies. J Neurol 2023;:1-12. [PMID: 36933032 DOI: 10.1007/s00415-023-11575-8] [Reference Citation Analysis]
3 Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. Vaccines 2023;11:682. [DOI: 10.3390/vaccines11030682] [Reference Citation Analysis]
4 Rachman A, Iriani A, Irawan C, Sukrisman L, Rajabto W, Mulansari NA, Lubis AM, Prasetyawaty F, Cahyanur R, Priantono D, Rumondor BB, Betsy R, Juanputra S. Complete blood count derived inflammatory biomarkers and the level of anti-SARS-CoV-2 NAb and S-RBD IgG among cancer survivors receiving COVID-19 vaccines. ELECTRON J GEN MED 2023;20:em456. [DOI: 10.29333/ejgm/12851] [Reference Citation Analysis]
5 Bhattacharya M, Chatterjee S, Lee SS, Chakraborty C. Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update. Int J Biol Macromol 2023;229:70-80. [PMID: 36586649 DOI: 10.1016/j.ijbiomac.2022.12.284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Menezes Dos Reis L, Berçot MR, Castelucci BG, Martins AJE, Castro G, Moraes-Vieira PM. Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies. Viruses 2023;15. [PMID: 36851739 DOI: 10.3390/v15020525] [Reference Citation Analysis]
7 Scendoni R, Cingolani M. What do we know about pathological mechanism and pattern of lung injury related to SARS-CoV-2 Omicron variant? Diagn Pathol 2023;18:18. [PMID: 36765347 DOI: 10.1186/s13000-023-01306-y] [Reference Citation Analysis]
8 Spinardi JR, Srivastava A. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines 2023;11. [PMID: 36830907 DOI: 10.3390/biomedicines11020370] [Reference Citation Analysis]
9 Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses 2023;15. [PMID: 36680207 DOI: 10.3390/v15010167] [Reference Citation Analysis]
10 Moulana A, Dupic T, Phillips AM, Chang J, Roffler AA, Greaney AJ, Starr TN, Bloom JD, Desai MM. The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. Elife 2023;12. [PMID: 36803543 DOI: 10.7554/eLife.83442] [Reference Citation Analysis]
11 Bhattacharya M, Chatterjee S, Sharma AR, Lee SS, Chakraborty C. Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape. Folia Microbiol (Praha) 2023;68:17-28. [PMID: 35962276 DOI: 10.1007/s12223-022-01001-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Trombetta CM, Marchi S, Leonardi M, Stufano A, Lorusso E, Montomoli E, Decaro N, Buonvino N, Lovreglio P. Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. Hum Vaccin Immunother 2022;18:2153537. [PMID: 36503363 DOI: 10.1080/21645515.2022.2153537] [Reference Citation Analysis]
13 Li M, Ge H, Sun Z, Fu J, Cao L, Feng X, Meng G, Peng Y, Liu Y, Zhao C. A loop-mediated isothermal amplification-enabled analytical assay for the detection of SARS-CoV-2: A review. Front Cell Infect Microbiol 2022;12:1068015. [PMID: 36619749 DOI: 10.3389/fcimb.2022.1068015] [Reference Citation Analysis]
14 Wang H, Lan Y. The Global Dynamic Transmissibility of COVID-19 and its Influencing Factors: an Analysis of Control Measures from 176 Countries.. [DOI: 10.21203/rs.3.rs-2197619/v1] [Reference Citation Analysis]
15 Chakraborty C, Bhattacharya M, Sharma AR, Dhama K, Lee S. The rapid emergence of multiple sublineages of Omicron (B.1.1.529) variant: Dynamic profiling via molecular phylogenetics and mutational landscape studies. Journal of Infection and Public Health 2022;15:1234-1258. [DOI: 10.1016/j.jiph.2022.10.004] [Reference Citation Analysis]
16 Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 2022;29:82. [PMID: 36243868 DOI: 10.1186/s12929-022-00853-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Hou XC, Xu HF, Liu Y, Sun P, Ding LW, Yue JJ, Wang TT, Gong X, Wu J, Liu B. A Vaccine with Multiple Receptor-Binding Domain Subunit Mutations Induces Broad-Spectrum Immune Response against SARS-CoV-2 Variants of Concern. Vaccines (Basel) 2022;10:1653. [PMID: 36298518 DOI: 10.3390/vaccines10101653] [Reference Citation Analysis]
18 Moulana A, Dupic T, Phillips AM, Chang J, Roffler AA, Greaney AJ, Starr TN, Bloom JD, Desai MM. The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution.. [DOI: 10.1101/2022.09.13.507781] [Reference Citation Analysis]
19 Wang J, Li Q, Qiu Y, Lu H. COVID-19: imbalanced cell-mediated immune response drives to immunopathology. Emerg Microbes Infect 2022;:1-28. [PMID: 36069182 DOI: 10.1080/22221751.2022.2122579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chakraborty C, Bhattacharya M, Sharma AR, Dhama K, Agoramoorthy G. A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs. Geroscience 2022;44:2393-425. [PMID: 35989365 DOI: 10.1007/s11357-022-00631-2] [Reference Citation Analysis]
21 Chakraborty C, Bhattacharya M, Sharma AR, Mallik B. Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol 2022;219:980-97. [PMID: 35952818 DOI: 10.1016/j.ijbiomac.2022.07.254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chakraborty C, Bhattacharya M, Sharma AR, Dhama K, Lee SS. Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron. Geroscience 2022;44:2371-92. [PMID: 35831773 DOI: 10.1007/s11357-022-00619-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chakraborty C, Sharma AR, Bhattacharya M, Mallik B, Nandi SS, Lee SS. Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. Infect Genet Evol 2022;101:105282. [PMID: 35427787 DOI: 10.1016/j.meegid.2022.105282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune Response to SARS-CoV-2 Vaccines. Biomedicines 2022;10:1464. [DOI: 10.3390/biomedicines10071464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open 2022;5:e2210780. [PMID: 35532938 DOI: 10.1001/jamanetworkopen.2022.10780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]